41. Black WC, Gareen IF, Soneji SS, et al. Cost-Effectiveness of CT Screening in the National Lung

Screening Trial. N Engl J Med 2014;371(19):1793–1802.

42. Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice

guidelines (2 nd edition). Chest 2007;132(3_suppl):131S–148S.

43. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical

resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet

2009;374(9687):379–386.

44. Mountain C, Dresler C. Regional lymph node classification for lung cancer staging. Chest

1997;111(6):1718–1723.

45. Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer:

ACCP evidenced-based clinical practice guidelines (2 nd edition). Chest 2007;132(3_suppl):178S201S.

46. Gonzalez-Stawinski GV, Lemaire A, Merchant F, et al. A comparative analysis of positron emission

tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg

2003;126(6):1900–1904.

47. Kernstine KH, McLaughlin KA, Menda Y, et al. Can FDG-PET reduce the need for mediastinoscopy

in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg 2002;73(2):394–402.

48. Vesselle H, Pugsley JM, Vallieres E, et al. The impact of fluorodeoxyglucose F 18 positron-emission

tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg

2002;124(3):511–519.

49. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology

Group Z0050 trial: the utility of positron emission tomography in staging potentially operable nonsmall cell lung cancer. J Thorac Cardiovasc Surg 2003;126(6):1943–1951.

50. Kozower BD, Meyers BF, Reed CE, et al. Does positron emission tomography prevent

nontherapeutic pulmonary resections for clinical stage IA lung cancer? Ann Thorac Surg

2268

2008;85(4):1166–1170.

51. Cerfolio RJ, Ojha B, Bryant AS, et al. The accuracy of integrated PET-CT compared with dedicated

pet alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg

2004;78(3):1017–1023.

52. Krasna MJ, Reed CE, Nugent WC, et al. Lung cancer staging and treatment in multidisciplinary

trials: cancer and leukemia group B cooperative group approach. Ann Thorac Surg 1999;68(1):201–

207.

53. Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasoundguided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph

node staging of lung cancer. J Thorac Cardiovasc Surg 2011;142(6):1393–1400.e1391.

54. Detterbeck FC, Jantz MA, Wallace M, et al. Invasive mediastinal staging of lung cancer: ACCP

evidence-based clinical practice guidelines (2 nd edition). Chest 2007;132(3_suppl):202S–220S.

55. Hammoud ZT, Anderson RC, Meyers BF, et al. The current role of mediastinoscopy in the

evaluation of thoracic disease. J Thorac Cardiovasc Surg 1999;118(5):894–899.

56. Postmus PE, Rocmans P, Asamura H, et al. Consensus report IASLC workshop Bruges, September

2002: pretreatment minimal staging for non-small cell lung cancer. Lung Cancer 2003;42(2,

Supplement 1):3–6.

57. Burfeind WR Jr, Tong BC, O’Branski E, et al. Quality of life outcomes are equivalent after

lobectomy in the elderly. J Thorac Cardiovasc Surg 2008;136(3):597–604.

58. Brunelli A, Cassivi SD, Fibla J, et al. External validation of the recalibrated thoracic revised cardiac

risk index for predicting the risk of major cardiac complications after lung resection. Ann Thorac

Surg 2011;92(2):445–448.

59. Miller JI, Grossman GD, Hatcher CR. Pulmonary function test criteria for operability and

pulmonary resection. Surg Gynecol Obstet 1981;153(6):893–895.

60. Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest

2003;123(6):2096–2103.

61. Pate P, Tenholder MF, Griffin JP, et al. Preoperative assessment of the high-risk patient for lung

resection. Ann Thorac Surg 1996;61(5):1494–1500.

62. Cerfolio RJ, Allen MS, Trastek VF, et al. Lung resection in patients with compromised pulmonary

function. Ann Thorac Surg 1996;62(2):348–351.

63. Burke JR, Duarte IG, Thourani VH, et al. Preoperative risk assessment for marginal patients

requiring pulmonary resection. Ann Thorac Surg 2003;76(5):1767–1773.

64. Loewen GM, Watson D, Kohman L, et al. Preoperative exercise Vo2 measurement for lung resection

candidates: results of Cancer and Leukemia Group B Protocol 9238. J Thorac Oncol 2007;2(7):619–

625.

65. Beckles MA, Spiro SG, Colice GL, et al. The physiologic evaluation of patients with lung cancer

being considered for resectional surgery. Chest 2003;123(90010):105S–114S.

66. Deslauriers J, Gregoire J, Jacques LF, et al. Sleeve lobectomy versus pneumonectomy for lung

cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg

2004;77(4):1152–1156.

67. Gaissert H, Mathisen D, Moncure A, et al. Survival and function after sleeve lobectomy for lung

cancer. J Thorac Cardiovasc Surg 1996;111(5):948–953.

68. Okada M, Yamagishi H, Satake S, et al. Survival related to lymph node involvement in lung cancer

after sleeve lobectomy compared with pneumonectomy. J Thorac Cardiovasc Surg 2000;119(4):814–

819.

69. Suen H-C, Meyers BF, Guthrie T, et al. Favorable results after sleeve lobectomy or bronchoplasty

for bronchial malignancies. Ann Thorac Surg 1999;67(6):1557–1562.

70. Yoshino I, Yokoyama H, Yano T, et al. Comparison of the surgical results of lobectomy with

bronchoplasty and pneumonectomy for lung cancer. J Surg Oncol 1997;64(1):32–35.

71. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 nonsmall cell lung cancer. Ann Thorac Surg 1995; 60(3):615–622.

72. Landreneau R, Sugarbaker D, Mack M, et al. Wedge resection versus lobectomy for stage I (T1 N0

M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997;113(4):691–700.

73. Yano T, Yokoyama H, Yoshino I, et al. Results of a limited resection for compromised or poor-risk

2269

patients with clinical stage I non-small cell carcinoma of the lung. J Am Coll Surg 1995;181(1):33–

37.

74. Altorki NK, Yip R, Hanaoka T, et al. Sublobar resection is equivalent to lobectomy for clinical stage

1 A lung cancer in solid nodules. J Thorac Cardiovasc Surg 2014;147(2):754–764.

75. Allen MS, Darling GE, Pechet TT, et al. Morbidity and mortality of major pulmonary resections in

patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030

trial. Ann Thorac Surg 2006;81(3):1013–1020.

76. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling

versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less

than hilar) non–small cell carcinoma: results of the American College of Surgery Oncology Group

Z0030 trial. J Thorac Cardiovasc Surg 2011;141(3):662–670.

77. Darling GE, Allen MS, Decker PA, et al. Number of lymph nodes harvested from a mediastinal

lymphadenectomy. Chest 2011;139(5):1124–1129.

78. Boffa DJ, Kosinski AS, Paul S, et al. Lymph node evaluation by open or video-assisted approaches in

11,500 anatomic lung cancer resections. Ann Thorac Surg 2012;94(2):347–353.

79. Robinson BM, Kennedy C, McLean J, et al. Node-negative non-small cell lung cancer: pathological

staging and survival in 1765 consecutive cases. J Thorac Oncol 2011;6(10):1691–1696.

80. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced

non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3(12):1468–1481.

81. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in

resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109(1):120–129.

82. Thomas P, Rubinstein L. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung

Cancer Study Group. Ann Thorac Surg 1990;49(2):242–246.

83. Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer

Inst 1998;90(18):1335–1345.

84. Rice D, Kim H-W, Sabichi A, et al. The risk of second primary tumors after resection of stage I

nonsmall cell lung cancer. Ann Thorac Surg 2003;76(4):1001–1008.

85. Colt HG, Murgu SD, Korst RJ, et al. Follow-up and surveillance of the patient with lung cancer after

curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of

Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e437S–454S.

86. Kent MS, Korn P, Port JL, et al. Cost effectiveness of chest computed tomography after lung cancer

resection: a decision analysis model. Ann Thorac Surg 2005;80(4):1215–1223.

87. Gail MH. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in

patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large

cell carcinoma of the lung. LCSG Protocol 771. Chest 1994;106(6 Suppl):287S–292S.

88. Ludwig Lung Cancer Study Group. Adverse effect of intrapleural Corynebacterium parvum as

adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. J Thorac Cardiovasc

Surg 1985;89(6):842–847.

89. Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumorinfiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of

resected nonsmall cell lung carcinoma. Cancer 1996;78(2):244–251.

90. Green N, Kurohara SS, George FW 3rd, et al. Postresection irradiation for primary lung cancer: the

impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung

carcinoma with ipsilateral mediastinal lymph node involvement. Radiology 1975;116(02):405–407.

91. Kirsh M, Rotman H, Argenta L, et al. Carcinoma of the lung: results of treatment over ten years.

Ann Thorac Surg 1976;21(5):371–377.

92. Sawyer TE, Bonner JA, Gould PM, et al. The impact of surgical adjuvant thoracic radiation therapy

for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node

involvement. Cancer 1997;80(8):1399–1408.

93. Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoperative radiotherapy in radically resected nonsmall cell lung cancer. Chest 1997;112(4):954–959.

94. Stephens RJ, Girling DJ, Bleehen NM, et al. The role of post-operative radiotherapy in non-smallcell lung cancer: a multicentre randomised trial in patients with pathologically staged T1–2, N1–2,

M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 1996;74(4):632–

2270

639.

95. Lafitte JJ, Ribet ME, Prevost BM, et al. Postresection irradiation for T2 N0 M0 non-small cell

carcinoma: a prospective, randomized study. Ann Thorac Surg 1996;62(3):830–834.

96. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely

resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986;315(22):1377–

1381.

97. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung caner: a

controlled trial after resection of curative design. Int J Rad Oncol Biol Phys 1980;6(8):983–986.

98. PORT Meta-analysis Trialist Group. Postoperative radiotherapy in non-small-cell lung cancer:

systematic review and meta-analysis of individual patient data from nine randomised controlled

trials. Lancet 1998;352(9124):257–263.

99. Burdett S, Stewart L, Group PM. Postoperative radiotherapy in non-small-cell lung cancer: update

of an individual patient data meta-analysis. Lung Cancer 2005;47(1):81–83.

100. Hughes FA, Higgins G. Veterans Administration Surgical Adjuvant Lung Cancer Chemotherapy

Study: present status. J Thorac Cardiovasc Surg 1962;44:295–304.

101. Slack NH. Bronchogenic carcinoma: nitrogen mustard as a surgical adjuvant and factors influencing

survival. University surgical adjuvant lung project. Cancer 1970;25(5):987–1002.

102. Shields TW, Humphrey EW, Eastridge CE, et al. Adjuvant cancer chemotherapy after resection of

carcinoma of the lung. Cancer 1977;40(5):2057–2062.

103. Shields TW, Higgins GA Jr., Humphrey EW, et al. Prolonged intermittent adjuvant chemotherapy

with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer 1982;50(9):1713–

1721.

104. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a

meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ

1995;311(7010):899–909.

105. Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin,

and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung

Cancer Study Group. J Natl Cancer Inst 1993;85(4):299–306.

106. Pisters KM, Kris MG, Gralla RJ, et al. Randomized trial comparing postoperative chemotherapy

with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) nonsmall cell lung cancer. J Surg Oncol 1994;56(4):236–241.

107. Dautzenberg B, Chastang C, Arriagada R, et al. Adjuvant radiotherapy versus combined sequential

chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma.

a randomized trial of 267 patients. GETCB (Groupe d’Etude et de Traitement des Cancers

Bronchiques). Cancer 1995;76(5):779–786.

108. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell

lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 1996;14(4):1048–1054.

109. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in

patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med

2000;343(17):1217–1222.

110. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely

resected stage I, II, or IIIa non-small-cell lung cancer. J Natl Cancer Inst 2003;95(19):1453–1461.

111. Wakelee H, Chhatwani L. Adjuvant chemotherapy for resected non-small cell lung cancer. Semin

Thorac Cardiovasc Surg 2008;20(3):198–203.

112. Nakagawa M, Tanaka F, Tsubota N, et al. A randomized phase III trial of adjuvant chemotherapy

with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan

Study Group for Lung Cancer Surgery (WJSG)–the 4th study. Ann Oncol 2005;16(1):75–80.

113. Alam N, Shepherd FA, Winton T, et al. Compliance with post-operative adjuvant chemotherapy in

non-small cell lung cancer: an analysis of National Cancer Institute of Canada and intergroup trial

JBR.10 and a review of the literature. Lung Cancer 2005;47(3):385–394.

114. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with

observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia

Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study

groups. J Clin Oncol 2008;26(31):5043–5051.

2271

115. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the International Adjuvant Lung

Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol

2010;28(1):35–42.

116. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by

the LACE Collaborative Group. J Clin Oncol 2008;26(21):3552–3559.

117. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative

radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

Lancet 2010;375(9722):1267–1277.

118. Petersen RP, Pham D, Burfeind WR, et al. Thoracoscopic lobectomy facilitates the delivery of

chemotherapy after resection for lung cancer. Ann Thorac Surg 2007;83(4):1245–1249.

119. Rendina EA, Venuta F, De Giacomo T, et al. Induction chemotherapy for T4 centrally located nonsmall cell lung cancer. J Thorac Cardiovasc Surg 1999;117(2):225–233.

120. Grunenwald DH, Andre F, Le Pechoux C, et al. Benefit of surgery after chemoradiotherapy in stage

IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122(4):796–802.

121. Collaud S, Waddell TK, Yasufuku K, et al. Long-term outcome after en bloc resection of non-smallcell lung cancer invading the pulmonary sulcus and spine. J Thorac Oncol 2013;8(12):1538–1544.

122. Okada M, Tsubota N, Yoshimura M, et al. Prognosis of completely resected pN2 non-small cell lung

carcinomas: what is the significant node that affects survival?J Thorac Cardiovasc Surg

1999;118(2):270–275.

123. Sagawa M, Sakurada A, Fujimura S, et al. Five-year survivors with resected pN2 nonsmall cell lung

carcinoma. Cancer 1999;85(4):864–868.

124. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative

chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J

Med 1994;330(3):153–158.

125. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell

lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26(1):7–14.

126. Roth J, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and

surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst

1994;86(9):673–680.

127. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized

trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA

non-small-cell lung cancer. Lung Cancer 1998;21(1):1–6.

128. Bromley LL, Szur L. Combined radiotherapy and resection for carcinoma of the bronchus;

experiences with 66 patients. Lancet 1955;269(6897):937–941.

129. Payne DG. Is preoperative or postoperative radiation therapy indicated in non-small cell cancer of

the lung? Lung Cancer 1994;10(Suppl 1):S205–S212.

130. Chang JY, Kestin LL, Barriger RB, et al. ACR Appropriateness criteria® nonsurgical treatment for

locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology

2014;28(8):706–722.

131. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential

radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28(13):2181–

2190.